Cohort plc Stock
Price
Target price
€16.80
€16.80
8.390%
1.3
8.390%
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Cohort plc Stock
Cohort plc dominated the market today, gaining €1.30 (8.390%).
Pros and Cons of Cohort plc in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
B****
Cons
?
S********** s********
?
C******** o* t** e**********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Cohort plc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Cohort plc | 8.390% | 30.233% | 18.310% | -5.085% | 57.009% | 208.257% | 136.620% |
| Computacenter plc | 4.420% | 6.122% | 18.721% | 66.667% | 51.163% | - | - |
| Softcat plc | 1.570% | 4.301% | 24.359% | -7.619% | 20.497% | 29.333% | -6.731% |
| NCC Group plc | 0.000% | -0.625% | 18.657% | -12.637% | 0.000% | 50.000% | -54.310% |
News
CG Oncology Touts Bladder Cancer Data, Q4 Filing Plans at RBC Conference
Key Points
- Interested in CG Oncology, Inc.? Here are five stocks we like better.
- Cohort CX data for cretostimogene plus gemcitabine showed a positive safety and efficacy signal in bladder
CG Oncology BLA Filing on Track as Key Bladder Cancer Data Nears
CG Oncology (NASDAQ:CGON) executives said the company remains on track to complete a rolling biologics license application for
Entrada Therapeutics DMD Trial Shows Early Functional Gains, Clean Safety Profile
Entrada Therapeutics (NASDAQ:TRDA) said initial data from the first cohort of its phase I/II ELEVATE-44-201 trial showed favorable